Background Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the Western world, and it is closely associated to obesity, type 2 diabetes mellitus, and dyslipidemia. Hepatocellular stellate cells (HSCs) activation by oxidative stress and inflammation is the hallmark of liver fibrosis and leads to cirrhosis and liver failure resistant to pharmacological management. Cannabinoids have been suggested as a potential therapy for liver fibrosis, prompting us to explore the antifibrotic and anti-inflammatory effects of Δ⁹-THCA-A, a major non-psychotropic cannabinoid from Cannabis sativa L., in animal models of NAFLD.

中文翻译：

---

Δ9-四氢大麻酚酸可明显减轻化学性和肥胖性肝损伤小鼠模型中的肝纤维化和炎症

背景技术非酒精性脂肪肝疾病（NAFLD）是西方世界最常见的肝病，它与肥胖症，2型糖尿病和血脂异常密切相关。氧化应激和炎症引起的肝星状细胞（HSC）活化是肝纤维化的标志，并导致肝硬化和对药理学治疗有抗性的肝衰竭。大麻素已被建议作为抗肝纤维化治疗的潜力，促使我们去探索Δ的抗纤维化和抗炎作用⁹ -THCA-A，由一个主要的非精神大麻大麻L.，在NAFLD的动物模型。